Spectrum of renal diseases associated with extreme forms of insulin resistance

被引:40
作者
Musso, Carla
Javor, Edward
Cochran, Elaine
Balow, James E.
Gorden, Phillip [1 ]
机构
[1] NIDDK, CEB, NIH, 9000 Rockville Pike,CRC Room 6-5952, Bethesda, MD 20892 USA
[2] NIDDK, Kidney Dis Sect, NIH, Bethesda, MD 20892 USA
来源
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2006年 / 1卷 / 04期
关键词
D O I
10.2215/CJN.01271005
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Diabetic nephropathy is the leading cause of ESRD in the United States. Why the pathogenic mechanisms lead to nephropathy in certain patients with type 1 and 2 diabetes and spare others is unclear, but it is clear that hyperglycemia and glomerular hyperfiltration are important factors. In patients with syndromes of extreme insulin resistance, proteinuric forms of renal disease are common, but it is surprising to find that the renal pathology usually is not diabetic nephropathy. For instance, in the lipodystrophy syndromes, membranoproliferative glomerulonephritis type 1 and type 2, focal segmental glomerulosclerosis, and also diabetic nephropathy are seen. In the syndromes of autoantibodies to the insulin receptor, the various forms of lupus glomerulonephritis are seen. Even in patients with type 2 diabetes, the renal pathology may not be diabetic nephropathy. Therefore, in patients with syndromic forms of insulin resistance and type 2 diabetes, renal biopsy has an important role in defining the pathology that leads to proteinuric nephropathy and in formulating a therapeutic approach. It is the purpose of this article to review these unusual aspects of proteinuric nephropathy in patients with diabetes.
引用
收藏
页码:616 / 622
页数:7
相关论文
共 40 条
[1]
Use of rituximab in two unusual antibody-mediated autoimmune disorders [J].
Adler, M ;
Soliotis, F ;
Thakrar, S ;
Stratton, R .
JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 2005, 98 (06) :271-272
[2]
Amer Diabet Assoc, 2005, DIABETES CARE, V28, pS37
[3]
Clinical course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance) [J].
Arioglu, E ;
Andewelt, A ;
Diabo, C ;
Bell, M ;
Taylor, SI ;
Gorden, P .
MEDICINE, 2002, 81 (02) :87-100
[4]
Boner G, 1996, DIABETOLOGIA, V39, P587
[5]
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[6]
The pathobiology of diabetic complications - A unifying mechanism [J].
Brownlee, M .
DIABETES, 2005, 54 (06) :1615-1625
[7]
RENAL-TRANSPLANTATION IN A PATIENT WITH LIPOATROPHIC DIABETES - CASE-REPORT [J].
CASALI, RE ;
RESNICK, J ;
GOETZ, F ;
SIMMONS, RL ;
NAJARIAN, JS ;
KJELLSTRAND, C .
TRANSPLANTATION, 1978, 26 (03) :174-177
[8]
Rituximab therapy for the type B syndrome of severe insulin resistance [J].
Coll, AP ;
Thomas, S ;
Mufti, GJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (03) :310-311
[9]
Medical progress - Acquired and inherited lipodystrophies [J].
Garg, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (12) :1220-1234
[10]
A family with severe insulin resistance and diabetes due to a mutation in AKT2 [J].
George, S ;
Rochford, JJ ;
Wolfrum, C ;
Gray, SL ;
Schinner, S ;
Wilson, JC ;
Soos, MA ;
Murgatroyd, PR ;
Williams, RM ;
Acerini, CL ;
Dunger, DB ;
Barford, D ;
Umpleby, AM ;
Wareham, NJ ;
Davies, HA ;
Schafer, AJ ;
Stoffel, M ;
O'Rahilly, S ;
Barroso, I .
SCIENCE, 2004, 304 (5675) :1325-1328